Krystal Biotech Inc (KRYS)
Days of sales outstanding (DSO)
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Receivables turnover | 2.83 | 1.33 | — | — | — | |
| DSO | days | 128.86 | 275.17 | — | — | — |
December 31, 2024 calculation
DSO = 365 ÷ Receivables turnover
= 365 ÷ 2.83
= 128.86
Based on the provided data, Krystal Biotech Inc's Days Sales Outstanding (DSO) has shown fluctuations over the years. The DSO was not available for analysis in 2020 and 2021 as indicated by "— days". In 2022, the DSO remained unavailable for analysis.
In December 31, 2023, the DSO was calculated at 275.17 days, indicating that on average, it takes the company approximately 275 days to collect its accounts receivable. This suggests a lengthy collection period, which may raise concerns about the company's efficiency in managing its receivables.
However, there was a significant improvement in the DSO in December 31, 2024, with the metric decreasing to 128.86 days. This reduction indicates that the company has improved its collection processes and is potentially becoming more efficient in collecting receivables.
Overall, the trend in DSO for Krystal Biotech Inc shows some variability, with a substantial decrease observed in 2024, suggesting a potential positive impact on the company's cash flow and working capital management. It is essential for the company to continue monitoring and managing its DSO to ensure efficient cash flow operations.
Peer comparison
Dec 31, 2024